The dosage of Camzyos (mavacamten) for hypertrophic cardiomyopathy is determined through a combination of clinical trial data, patient-specific factors, and ongoing PK/PD monitoring. Initial dosages typically start at 2.5 to 5 mg/day, with adjustments based on therapeutic response and safety assessments

Not applicable

Common Side Effects: Dizziness or lightheadedness – This can occur due to its effect on lowering heart rate and blood pressure. Fatigue – Feeling unusually tired is a common reaction as the medication reduces the force of the heart's contractions. Shortness of breath – Though it aims to improve symptoms of obstructive HCM, in some cases it may cause or worsen breathing difficulties. Headache – A general headache may occur as a result of the body's adjustment to the medication. Low blood pressure (hypotension) – CAMZYOS can lower blood pressure, leading to symptoms such as lightheadedness or fainting. Serious Side Effects: Heart failure – CAMZYOS can affect heart function, sometimes causing or worsening heart failure, particularly if there is already some form of cardiac impairment. Arrhythmias – Irregular heart rhythms may develop, which could be serious and require medical attention. Bradycardia – A significantly slowed heart rate, which may require adjustment of the dosage or discontinuation. Additional Notable Side Effects: Decreased Left Ventricular Ejection Fraction (LVEF) – Noted in clinical trials as a significant side effect, especially at higher plasma concentrations 4 9. Atrial Fibrillation – Reported as a possible side effect, particularly at higher doses 4.